Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.44 |
| ▸ | DPP4 | P27487 | 5/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NRP1 | O14786 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | FPR3 | P25089 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7422812 | 0.81 | DPP4 (0.35) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL6175048 | 0.78 | DPP7 (0.56) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL7257356 | 0.78 | DPP7 (0.56) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL6172701 | 0.74 | DPP7 (0.57) | DPP7DPP4DPP8DPP9MAOA | |
| SCHEMBL7189181 | 0.73 | DPP4 (0.40) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL6174604 | 0.73 | DPP4 (0.40) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL6174600 | 0.73 | DPP4 (0.40) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL7186525 | 0.72 | DPP7 (0.37) | DPP7DPP4DPP8DPP9GAA | |
| SCHEMBL6488699 | 0.72 | DPP7 (0.37) | DPP7DPP4DPP8DPP9GAA | |
| SCHEMBL7290477 | 0.72 | DPP4 (0.48) | DPP7DPP4DPP8DPP9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465891-A4 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARM INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | GUILFORD PHARMACEUTICALS | 2005-03-31 | — | — | US | disclosed |
| EP-1465891-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-6645995-B2 | Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine | NOVO NORDISK A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| WO-2003057666-A2 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | GUILFORD PHARMACEUTICALS (US) | 2003-07-17 | — | — | WO | disclosed |
| EP-1254113-A1 | N-SUBSTITUTED 2-CYANOPYROLES AND -PYRROLINES WHICH ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS (DK) | 2002-08-01 | — | — | US | disclosed |
| US-6380398-B2 | COMPOUNDS SUCH AS (S,S)1-(2-AMINO-3,3-DIMETHYL-BUTYRYL)-2,5-DIHYDRO-1H-PYRROLE-2 -CARBONITRILE ADMINISTERED AS ANTIDIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2001-10-18 | — | — | US | disclosed |
| WO-2001055105-A1 | N-SUBSTITUTED 2-CYANOPYROLES AND -PYRROLINES WHICH ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP7 2/4885DPP4 1/4885DPP8 5/4885 |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | DPP7 2/4885DPP4 1/4885DPP8 5/4885 |
| US-20050070719-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP3, DPP7 | DPP7 3/4885DPP4 1/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.